|1994 - The company was incorporated as a manufacturer of natural products and chemicals.
2004 - Members at the annual general meeting of the company had approved the increase in authorized share capital from Rs 4.5 crore to 7.5 crore.
- The company had an agreement of understanding (AOU) with Zhejiang Hisun Pharmaceuticals Company Ltd. of China in the field of development and sales of anti cancer compounds, their intermediates and penultimates.
2005 - The company had signed an agreement of cooperation and agency with Allessa Chemie of Germany.
- The company had planned to raise USD25 million through the issue of Foreign Currency Convertible Bonds (FCCBs).
- The company had authorized its board to borrow up to Rs 250 crore.
- The company had increased its authorized share capital from Rs 7.5 crore to Rs 15 crore.
2006 - The company had completed the technology transfer for synthesis of iminostilbenes, an intermediate widely used in different tricycle anti-depressants, to Changshu Wanxing Chemical Company of China.
2007 - Board of directors of the company on 27th October 2007 had accepted resignation letter of Dr. R K Dhar from the directorship as well as CEO of the company, with immediate effect.
-Mr. Rajesh Sharma was appointed as additional director of the company.
2008 - Board of directors of the company had approved to issue 14,00,000 warrants, as 8,00,000 warrants to the promoters and to the person acting in concert and 6,00,000 warrants to the persons other than the promoters.